[go: up one dir, main page]

BRPI0606492A2 - método de uso de compostos agonistas duplos de ppars e dispositivos para distribuição de fármacos que contêm tais compostos - Google Patents

método de uso de compostos agonistas duplos de ppars e dispositivos para distribuição de fármacos que contêm tais compostos

Info

Publication number
BRPI0606492A2
BRPI0606492A2 BRPI0606492-2A BRPI0606492A BRPI0606492A2 BR PI0606492 A2 BRPI0606492 A2 BR PI0606492A2 BR PI0606492 A BRPI0606492 A BR PI0606492A BR PI0606492 A2 BRPI0606492 A2 BR PI0606492A2
Authority
BR
Brazil
Prior art keywords
compounds
dual
delivery devices
pair
drug delivery
Prior art date
Application number
BRPI0606492-2A
Other languages
English (en)
Inventor
David Saul Cohen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36572137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0606492(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0606492A2 publication Critical patent/BRPI0606492A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

MéTODO DE USO DE COMPOSTOS AGONISTAS DUPLOS DE PPARs E DISPOSITIVOS PARA DISTRIBUIçãO DE FáRMACOS QUE CONTêM TAIS COMPOSTOS. A presente invenção refere-se a usos de compostos agonistas duplos de PPARs e dispositivos de distribuição que contêm tais compostos. Os compostos são úteis como produtos farmacêuticos para o tratamento e/ou prevenção de proliferação de VSMCs, como por exemplo, estenose e restenose, especialmente restenose em pacientes diabéticos.
BRPI0606492-2A 2005-01-18 2006-01-17 método de uso de compostos agonistas duplos de ppars e dispositivos para distribuição de fármacos que contêm tais compostos BRPI0606492A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64464605P 2005-01-18 2005-01-18
PCT/US2006/001506 WO2006078605A1 (en) 2005-01-18 2006-01-17 Methods of use of dual ppar agonist compounds and drug delivery devices containing such compounds

Publications (1)

Publication Number Publication Date
BRPI0606492A2 true BRPI0606492A2 (pt) 2009-06-30

Family

ID=36572137

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606492-2A BRPI0606492A2 (pt) 2005-01-18 2006-01-17 método de uso de compostos agonistas duplos de ppars e dispositivos para distribuição de fármacos que contêm tais compostos

Country Status (17)

Country Link
US (1) US20080131475A1 (pt)
EP (1) EP1841422A1 (pt)
JP (1) JP2008527008A (pt)
KR (1) KR20070094628A (pt)
CN (1) CN101102764A (pt)
AU (1) AU2006206682A1 (pt)
BR (1) BRPI0606492A2 (pt)
CA (1) CA2593483A1 (pt)
IL (1) IL184274A0 (pt)
MA (1) MA29172B1 (pt)
MX (1) MX2007008680A (pt)
NO (1) NO20074049L (pt)
RU (1) RU2007131501A (pt)
TN (1) TNSN07273A1 (pt)
TW (1) TW200637543A (pt)
WO (1) WO2006078605A1 (pt)
ZA (1) ZA200704752B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3398599A1 (en) 2009-03-11 2018-11-07 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20130197043A1 (en) 2010-08-31 2013-08-01 Snu R&Db Foundation Use of the fetal reprogramming of a ppar agonist

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020127263A1 (en) * 2001-02-27 2002-09-12 Wenda Carlyle Peroxisome proliferator-acitvated receptor gamma ligand eluting medical device
AU2002254940A1 (en) * 2001-03-12 2002-09-24 Novartis Pharma Gmbh Combination of nateglinide or repaglinide with at least one further antidiabetic compound
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds
DE10229777A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
DE10237571A1 (de) * 2002-08-13 2004-02-26 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin Endovaskuläres Implantat mit aktiver Beschichtung
CA2512879A1 (en) * 2003-01-17 2004-08-12 Soumya P. Sahoo N-cyclohexylaminocarbonyl benzenesulfonamide derivatives

Also Published As

Publication number Publication date
US20080131475A1 (en) 2008-06-05
IL184274A0 (en) 2007-10-31
JP2008527008A (ja) 2008-07-24
RU2007131501A (ru) 2009-02-27
MA29172B1 (fr) 2008-01-02
TNSN07273A1 (en) 2008-12-31
WO2006078605A1 (en) 2006-07-27
NO20074049L (no) 2007-10-16
EP1841422A1 (en) 2007-10-10
AU2006206682A1 (en) 2006-07-27
KR20070094628A (ko) 2007-09-20
CN101102764A (zh) 2008-01-09
MX2007008680A (es) 2007-07-25
ZA200704752B (en) 2008-05-28
CA2593483A1 (en) 2006-07-27
TW200637543A (en) 2006-11-01

Similar Documents

Publication Publication Date Title
BR112012010270A2 (pt) mentisulfonilmetano (msm) para tratamento de micro-organismos resistentes a fármaco
CL2007002649A1 (es) Composicion farmaceutica que comprende 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo; y uso para el tratamiento de la diabetes.
CL2007003495A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer.
CL2007003803A1 (es) Compuestos derivados de sulfonamidas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer, dislipidemia, diabetes, obesidad, infeccion.
MX2010007936A (es) Anticuerpo anti-nr-10 y su uso.
PA8840801A1 (es) Derivaos de dioxa-biciclo[3.2.1]octano-2,3,4-triol
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
CL2007002890A1 (es) Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad.
DOP2006000269A (es) Derivados de 4-amino-pirrolotriazina sustituida útiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogénesis
CL2009000967A1 (es) Compuesto 4-ciclobutil-n-((2s,5r)-5-hidroxi-2-adamantil)-2-morfolin-4-ilpiridin-5-carboxamida, inhibidor de la enzima 11betahsd1; composicion farmaceutica que lo comprende; y su uso en un procedimiento de tratamiento profilactico o terapeutico de un animal de sangre caliente.
UY30759A1 (es) Compuestos quimicos
CL2008001271A1 (es) Compuestos derivados de heterociclos de nitrogeno y oxigeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, hiperglicemia, intolerancia a la glucosa, aterosclerosis, dislipidemia, obesid
CL2007003666A1 (es) Compuestos derivados del acido nicotinico; composicion farmaceutica que comprende a dichos compuestos; combinacion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis, esclerosis multiple, psoriasis, entre otras.
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CL2007001915A1 (es) Compuesto cristalino de 6-[4-cloro-3-(4-etoxibencil)fenil]tetrahidropiran-2,3,4,5,-tetraol; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y su uso para preparar un medicamento para tratar diabetes, dislipidemia, obesidad, entre otras.
CL2011001094A1 (es) Compuesto derivados de pirazin-2-iloxi, inhibidores de pde10; composición farmacéutica que comprende a los compuestos; y uso de los compuestos en la preparación de medicamentos para tratar enfermedades, tales como obesidad, diabetes no dependiente de insulina, esquizofernia, bipolaridad, trastorno obsesivo-compulsivo y similares.
CL2012001762A1 (es) Compuestos derivados de pirazina, con actividad inhibidora de bace; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de enfermedad de alzheimer o deterioro cognitivo leve.
CL2007002187A1 (es) Compuestos derivados espirocetal sustituidos; composicion farmaceutica que comprende a dicho compuesto; y su uso para el tratamiento de la diabetes, hiperglicemia, complicaciones diabeticas y obesidad.
CL2008000691A1 (es) Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades.
DOP2011000176A (es) Compuestos organicos
BRPI0615150A2 (pt) agente para a profilaxia ou tratamento de diabete, sensibilizador de insulina, composto, pró-droga, agente farmacêutico, e, uso do composto ou um sal do mesmo ou uma pró-droga do mesmo
CL2007002682A1 (es) Compuestos derivados de 4-metilpiridopirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el crecimiento anormal de celulas, como cancer.
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
CR10336A (es) Compuestos organicos y sus usos
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.